Use of a c-Met-targeting aptamer-drug conjugate for efficient therapy in both primary and metastatic uveal melanoma.
Abstract
Uveal melanoma (UM), the most common primary intraocular malignancy in adults, is associated with a high risk of metastasis, recurrence, and irreversible vision loss. However, current therapeutic options remain limited by insufficient efficacy and poor vision preservation. Building upon the molecular design of SL1-MMAE, a c-Met-targeting aptamer-drug conjugate (ApDC), here we investigate its potential translational application as a targeted therapeutic strategy for both primary and metastatic UM. SL1-MMAE exhibits high binding specificity, rapid cellular internalization, and potent cytotoxicity toward UM cells in vitro. In vivo, SL1-MMAE effectively suppresses tumor growth in both subcutaneous xenograft and liver metastasis models, significantly prolonging survival. Notably, in an orthotopic intraocular UM model, a single intravitreal injection of SL1-MMAE induces robust tumor regression without detectable ocular toxicity at the therapeutic dose. The small molecular size of the ApDC enables superior tumor penetration and reduced retention from non-target ocular tissues. These features are particularly advantageous within the confined intraocular environment, leading to enhanced therapeutic efficacy with improved safety. Compared with the clinically advanced c-Met antibody-drug conjugate (ADC) ABBV-399, the ApDC demonstrates superior antitumor activity and ocular biocompatibility for intraocular UM therapy. Nevertheless, as a preclinical study, further safety, pharmacokinetic and translational studies are warranted to better define the clinical potential of SL1-MMAE. Collectively, these findings establish c-Met-targeting ApDCs as a promising platform for the treatment of both primary and metastatic UM, offering a vision-preserving therapeutic strategy with potent antitumor efficacy and favorable safety profiles.